Entrada Therapeutics reports 0.10% mean dystrophin increase in 5 mg/kg cohort of Phase 1/2 Duchenne trial of ENTR-601-45

Entrada Therapeutics reported a 0.10% mean dystrophin increase in the 5 mg/kg cohort of its Phase 1/2 Duchenne muscular dystrophy trial of ENTR-601-45, with the primary safety goal met.

Detected & updated continuously · Source: Nebula